Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Expert Emphasizes Healthy Lifestyle in Prostate Cancer Care

In an era of multidisciplinary care, it is important to incorporate healthcare experts to help encourage patients with cancer to... Read More

Expert Discusses Optimizing HIFU and Other Strategies in Prostate Cancer

Although High-intensity focused ultrasound (HIFU) is only approved in the United States for prostate tissue ablation, it has demonstrated efficacy... Read More

Considerations for Initiating ADT in Prostate Cancer

Watch the panel.

Apalutamide Added to NCCN Prostate Cancer Guidelines

The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate... Read More

2018 Ushers in New Era of Prostate Cancer Treatment

Upfront taxane-based chemotherapy with docetaxel improved survival in patients with metastatic prostate cancer, according to phase III findings from the... Read More

Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer

Brachytherapy-based radiotherapy and radical prostatectomy produced similar survival results for men with high-risk, localized prostate cancer, according to findings published... Read More

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

Preliminary data suggest that patients with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when... Read More

Dr. Wise on AR-Directed Therapy for Prostate Cancer

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center,... Read More

Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer

Adding docetaxel to androgen-deprivation therapy (ADT) improved overall survival (OS) by nearly 17 months in men with high-volume metastatic hormone-sensitive... Read More

Dr. Mason on Treatment Decisions Following 10-Year PROTECT Data in Prostate Cancer

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy... Read More

1 2 3 4